Periostin promotes chemoresistance to cisplatin and 5-FU in gastric cancer cells through the Akt/p53 pathway [44] and enhances gemcitabine resistance in pancreatic cancer through the Akt/ERK pathway [45]. This evidence concerns the gene AKT1 and familial pancreatic carcinoma.